EUVIMEDSkopri EUVIMED
Klinische Studie (Phase III)Open access · CC BY-NC 4.0

Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST

Laurent Peyrin-Biroulet iD, Séverine Vermeire iD, Geert D'Haens, Julian Panés iD, Axel Dignass iD, Fernando Magro iD, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Frederic Lavie and 6 more

Alimentary Pharmacology & Therapeutics · 2024-01 · 59 (2) · 175-185

DOI: 10.1111/apt.17751 ↗

At a glance

Klinische Studie (Phase III) in Alimentary Pharmacology & Therapeutics, published online on 2023-11-30. Written by Laurent Peyrin-Biroulet and 17 co-authors. Institution: University of Lorraine, INSERM, NGERE, Nancy, France. Major MEDLINE topics: Ustekinumab, Crohn Disease. Cited 18 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Janssen-Cilag, Limited.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

STARDUST, a phase 3b randomised trial, compared ustekinumab therapeutic strategies in patients with Crohn's disease (CD) using early endoscopic assessment and treat‐to‐target (T2T) versus standard of care (SoC).

Aim

To assess the efficacy of ustekinumab extended treatment in a long‐term extension (LTE) of up to 104 weeks with dosing adapted according to clinical, biomarker and endoscopy outcomes.

Methods

Adults with moderately‐to‐severely active CD received intravenous ustekinumab approximating 6 mg/kg at Week 0 and subcutaneous ustekinumab 90 mg at Week 8. At Week 16, 440 ≥70‐point responders were randomised to T2T or SoC and 323 entered the LTE. At Week 48, a unified, protocol‐defined ustekinumab dose frequency escalation/de‐escalation was applied based on achieving endoscopic remission and corticosteroid‐free clinical remission. Achieving corticosteroid‐free clinical remission and biomarker remission at consecutive visits determined ustekinumab dosing frequency. Dichotomous variables were analysed using non‐responder imputation.

Results

Among patients who entered the LTE, 7.7%, 48.6% and 43.7% received doses every 4, 8 and 12 weeks, respectively. Ustekinumab dose frequency was escalated in 23.5% and de‐escalated in 19.7%. Endoscopic response and remission rates were 28.9% and 10.73% (all randomised) and 39.3% and 14.6% (patients entering the LTE), respectively, at Week 104. Clinical remission a rates at week 104 were 50.2% (all randomised) and 68.4% (patients entering the LTE). There were no new safety signals.

Conclusion

STARDUST LTE is the first interventional ustekinumab efficacy study to show a favourable benefit–risk profile with preservation of clinical and endoscopic outcomes through Week 104 using flexible, algorithm‐driven dose adjustment including de‐escalation.

Subjects

MeSH terms (MEDLINE)

UstekinumabCrohn DiseaseAdultHumansRemission InductionEndoscopy, GastrointestinalBiomarkersTreatment Outcome

Substances

UstekinumabBiomarkers

Authors and institutions

  • University of Lorraine, INSERM, NGERE, Nancy, France.
  • Groupe Hospitalier privé Ambroise Paré-Hartmann, Paris IBD Center, Neuilly sur Seine, France.
  • Department of Gastroenterology & Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
  • Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany.

ORCID profiles: Laurent Peyrin-Biroulet, Séverine Vermeire, Julian Panés, Axel Dignass, Fernando Magro, Marco Daperno, Alessandro Armuzzi, Silvio Danese

Funding

  • Janssen-Cilag, Limited

Cite

APA

Peyrin-Biroulet, L., Vermeire, S., D'Haens, G., Panés, J., Dignass, A., Magro, F., Nazar, M., Le Bars, M., Lahaye, M., Ni, L., Bravatà, I., Lavie, F., Daperno, M., Lukáš, M., Armuzzi, A., Löwenberg, M., Gaya, D. R., & Danese, S. (2024). Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics, 59(2), 175-185. https://doi.org/10.1111/apt.17751

Vancouver

Peyrin-Biroulet L, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, et al. Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics. 2024;59(2):175-185. doi:10.1111/apt.17751

BibTeX
@article{PeyrinBiroulet2024,
  author = {Peyrin-Biroulet, Laurent and Vermeire, Séverine and D'Haens, Geert and Panés, Julian and Dignass, Axel and Magro, Fernando and Nazar, Maciej and Le Bars, Manuela and Lahaye, Marjolein and Ni, Lioudmila and Bravatà, Ivana and Lavie, Frederic and Daperno, Marco and Lukáš, Milan and Armuzzi, Alessandro and Löwenberg, Mark and Gaya, Daniel R and Danese, Silvio},
  title = {Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {2},
  pages = {175--185},
  doi = {10.1111/apt.17751}
}
Start for free →